2019
Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma
Cornman-Homonoff J, Bassik N, Madoff DC. Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma. Clinical Imaging 2019, 59: 188-191. PMID: 31837541, DOI: 10.1016/j.clinimag.2019.09.012.Peer-Reviewed Case Reports and Technical NotesConceptsRecurrent cholangiocarcinomaOnly potential cureRecurrent intrahepatic cholangiocarcinomaPoor patient outcomesUnresectable diseaseGastrointestinal bleedingChemotherapy administrationMyelosuppressive effectsTherapeutic mainstayDismal prognosisIntrahepatic cholangiocarcinomaVariceal embolizationStent placementPortal veinPatient outcomesPotential cureCholangiocarcinomaEmbolizationCytopeniasBleedingRegimenChemotherapyPatientsSurgeryPrognosis
2011
High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2007
Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab
Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab. Journal Of Vascular And Interventional Radiology 2007, 18: 1588-1591. PMID: 18057297, DOI: 10.1016/j.jvir.2007.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabCetuximabColorectal NeoplasmsCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRadiopharmaceuticalsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsColorectal cancerTreatment experienceAdvanced unresectable colorectal cancerUnresectable colorectal cancerMetastatic colorectal cancerCohort of patientsYttrium-90 microspheresSystemic therapyBiologic agentsDrug AdministrationHepatic neoplasiaCetuximabPatientsCancerBevacizumabChemotherapyNeoplasiaTherapyCohortPhysiciansAdministration